This medical technology company supplies single-use devices for critical care and surgery to hospitals and healthcare providers worldwide.

Teleflex's TFX robust performance in the Interventional product line is poised to help it grow in the upcoming quarters. The Urolift system is seeing consistent growth in hospitals, with positive ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Teleflex (NYSE:TFX) in the last three months. The table below provides a snapshot of their ...

The stock's fall snapped a four-day winning streak.

Teleflex Incorporated, a diversified medical device company, saw a 17% stock drop after Q3 results in late October. The stock now trades at under 13.5 EPS (non-GAAP) and at the equity's lowest ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Teleflex (NYSE:TFX – Free Report) had its price objective lowered by Mizuho from $150.00 to $130.00 in a research report released on Wednesday,Benzinga reports. The brokerage currently has a neutral ...

Teleflex (NYSE:TFX – Get Free Report) was downgraded by research analysts at Raymond James from an “outperform” rating to a “market perform” rating in a report released on Friday, Marketbeat reports.

New, independent, publicly traded company (NewCo) consisting of Teleflex’s Urology, Acute Care, and OEM businesses. RemainCo will consist of Teleflex’s Vascular Access, Interventional, and Surgical ...

This was the stock's second consecutive day of losses.